Paralel Advisors LLC Buys New Position in Bristol Myers Squibb Company $BMY

Key Points

• Paralel Advisors LLC purchased 38,091 Bristol Myers Squibb shares worth approximately $2.2 million, while institutional investors and hedge funds collectively own 76.41% of the company.
• Bristol Myers Squibb reported stronger-than-expected quarterly results, with $2.04 in EPS and $12.97 billion in revenue. The company also pays a quarterly dividend of $0.63, representing an annualized yield of about 3.8%.
• Analysts maintain a generally positive outlook, reflected in a “Moderate Buy” consensus and an average price target of $66.06, but investors face risks including legacy-drug declines and a pause in zola-cel trials over inflammatory safety concerns.

Paralel Advisors LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 38,091 shares of the biopharmaceutical company's stock, valued at approximately $2,195,000.

Other hedge funds have also made changes to their positions in the company. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the second quarter valued at $25,000. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb during the 4th quarter worth about $25,000. Davis Asset Management L.P. purchased a new stake in Bristol Myers Squibb during the 2nd quarter worth about $27,000. Bayban acquired a new stake in Bristol Myers Squibb in the 4th quarter valued at about $31,000. Finally, Addison Advisors LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $32,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a Phase 2 trial evaluating a therapy in depression, expanding its pipeline into a large potential market. Positive clinical progress could provide a new growth opportunity if the treatment demonstrates efficacy and safety. Bristol-Myers Squibb Moves Into Depression Market With New Phase 2 Trial
• Positive Sentiment: Analysts and financial commentators continue to highlight BMY’s relatively low valuation, roughly 3.7% forward dividend yield, strong margins and growth products that are offsetting declines in older medicines. These factors support the stock’s defensive and income-oriented appeal. Bristol Myers Squibb: Still Cheap, Despite What The Chart Says
• Neutral Sentiment: Technical indicators have reportedly turned bullish, while RBC Capital maintained a Hold rating, indicating that analysts see some upside but remain cautious about the company’s outlook. Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
• Negative Sentiment: Bristol Myers Squibb paused enrollment in its zola-cel autoimmune cell-therapy trials after safety surveillance identified inflammatory side effects. Reports that the pause involved serious safety concerns raised questions about the program’s risk profile, development timeline and broader cell-therapy strategy. What Does Bristol Myers Squibb Trial Pause Mean For Its Pipeline?
• Negative Sentiment: The wider healthcare sector traded lower, adding industry-level pressure to BMY. Investors also continue to monitor legacy-drug declines, including Opdivo, and future Eliquis patent-expiry risks. Sector Update: Healthcare Stocks Decline Friday Afternoon

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BMY. Piper Sandler began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set an "overweight" rating for the company. Citigroup reiterated a "neutral" rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. Bank of America lowered their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a "buy" rating for the company in a report on Friday, July 10th. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research report on Wednesday, August 5th. Finally, Jefferies Financial Group cut shares of Bristol Myers Squibb from a "buy" rating to a "hold" rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $66.06.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company's stock, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Trading Up 0.0%

Shares of Bristol Myers Squibb stock opened at $66.85 on Monday. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The company has a fifty day simple moving average of $62.92 and a 200-day simple moving average of $59.92. The stock has a market cap of $136.56 billion, a price-to-earnings ratio of 14.72, a PEG ratio of 0.32 and a beta of 0.23. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb's quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. Bristol Myers Squibb's dividend payout ratio is 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source